| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 5.4 |
| Net income | -44.3 | -7.4 |
| EPS (diluted, $ a share) | $-0.76 | $-0.13 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: SPRO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Spero Therapeutics, Inc.: key numbers
- Share price
- $0.9464Close, Nov 16
- Market cap
- $55.1M
- Shares outstanding
- 58.26MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Spero Therapeutics, Inc.
All →Spero Therapeutics Financial Results
Spero Therapeutics reported third quarter 2026 financial results, ending the period with $107.9 million in cash and cash equivalents. The company is focused on advancing its in-licensed anti-CD40L antibody, SP001, toward a Phase 2 trial in IgG4-related disease expected to initiate in Q2 2027.
“We believe SP001 represents a compelling opportunity to address significant unmet medical needs across multiple immune-mediated diseases. With a strong financial position and the recent additions to our team that strengthen the capabilities needed to support our next stage of development, we believe we are well positioned to execute our clinical development strategy.”
Esther Rajavelu, President and Chief Executive Officer
Spero Therapeutics Insider Esther Rajavelu Sells $42.5K of Stock
Esther Rajavelu sold 40,851 shares of Spero Therapeutics, Inc. at $1.04 a share, worth $42.5K in total on Nov 9, 2026. Shares held after the trade: 946,000 (-4.1%).
- Value
- $42.5K
- Shares
- 40,851
- Price
- $1.04
- Holding change
- -4.1%
- Trade date
- Nov 9, 2026
Spero Therapeutics Leadership Change
Patrick Vink, M.D. resigned from the Board of Directors effective November 10, 2026, after 11 years of service. To fill the vacancy, the Board appointed William Ho, M.D., Ph.D., a former RAPT Therapeutics executive, as a Class II director and member of the Development Committee. Dr. Ho will receive an annual cash retainer of $45,000 and was granted an option to purchase 100,000 shares of common stock.
Spero Therapeutics Leadership Change
Timothy Keutzer, the Chief Operating Officer of Spero Therapeutics, will retire effective December 31, 2026, after 11 years with the company. Following his retirement, he will enter into a consulting arrangement to provide transition advisory services through February 28, 2027.